MAIA Announces Preliminary Efficacy Data From Ongoing THIO-101 Phase 2 Trial: Says '100% Preliminary DCR observed in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatment'
Portfolio Pulse from Benzinga Newsdesk
MAIA has announced preliminary efficacy data from its ongoing THIO-101 Phase 2 trial. The company reported a 100% preliminary Disease Control Rate (DCR) in second-line patients and 88% in third-line patients. These patients are considered highly difficult to treat as they have already progressed through previous lines of treatment.
October 24, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The preliminary data from MAIA's THIO-101 Phase 2 trial shows promising results, which could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to an increase in a biotech company's stock price as it indicates progress and potential future revenue. Given the high DCR reported, investors may see this as a positive sign for MAIA's future prospects.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100